This week in therapeutics




Licensing status

Publication and contact information


Allergy; allergic rhinitis; atopic dermatitis

S100 calcium binding protein A4 (S100A4)

Human and mouse studies suggest inhibiting S100A4 could help treat allergy. In patients with allergic rhinitis or allergic dermatitis, S100A4 levels in nasal fluid or skin lesions were higher than those in corresponding samples from healthy controls. In blood monocytes from the patients with rhinitis, an anti-S100A4 antibody decreased levels of allergy-associated, proinflammatory cytokines compared with pretreatment baselines. In mouse models of atopic dermatitis, the anti-S100A4 antibody decreased skin inflammation, leukocyte recruitment to the skin and draining lymph nodes, and circulating levels of T helper type 2 (Th2) cell IgG compared with an inactive antibody. Ongoing work includes investigating the role of S100A4 in asthma.
Lykera Biomed S.A. has LK-1, a humanized antibody against S100A4, in preclinical development to treat pancreatic cancer.

SciBX 7(4); doi:10.1038/scibx.2014.124
Published online Jan. 30, 2014

Unpatented; available for licensing

Bruhn, S. et al. Sci. Transl. Med.; published online Jan. 8, 2014;
Contact: Mikael Benson, Linkoeping University, Linkoeping, Sweden
Contact: Zou Xiang, University of Gothenburg, Gothenburg, Sweden